X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3119) 3119
Book Review (372) 372
Publication (198) 198
Conference Proceeding (11) 11
Magazine Article (9) 9
Book Chapter (4) 4
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2767) 2767
humans (2419) 2419
valine - analogs & derivatives (2263) 2263
valine - therapeutic use (1831) 1831
male (1562) 1562
female (1373) 1373
valsartan (1194) 1194
tetrazoles - therapeutic use (955) 955
middle aged (939) 939
acyclovir - analogs & derivatives (793) 793
animals (738) 738
adult (735) 735
acyclovir - therapeutic use (714) 714
antiviral agents - therapeutic use (699) 699
aged (678) 678
hypertension - drug therapy (569) 569
antihypertensive agents - therapeutic use (564) 564
pharmacology & pharmacy (528) 528
valine - pharmacology (517) 517
treatment outcome (479) 479
valine - administration & dosage (479) 479
angiotensin ii type 1 receptor blockers - therapeutic use (397) 397
drug therapy, combination (385) 385
rats (381) 381
hypertension (365) 365
blood pressure - drug effects (344) 344
abridged index medicus (332) 332
valine - adverse effects (323) 323
valine (312) 312
double-blind method (309) 309
tetrazoles - pharmacology (297) 297
tetrazoles - administration & dosage (249) 249
peripheral vascular disease (243) 243
valacyclovir (232) 232
mice (229) 229
time factors (221) 221
angiotensin-converting enzyme inhibitors - therapeutic use (220) 220
hypertension - physiopathology (209) 209
drug therapy (206) 206
valine - genetics (205) 205
dose-response relationship, drug (201) 201
cardiac & cardiovascular systems (197) 197
adolescent (194) 194
acyclovir (192) 192
medicine, general & internal (190) 190
tetrazoles - adverse effects (188) 188
risk factors (184) 184
analysis (179) 179
angiotensin receptor antagonists (172) 172
research (170) 170
antihypertensive agents - administration & dosage (169) 169
prospective studies (169) 169
acyclovir - administration & dosage (167) 167
double-blind (164) 164
heart failure - drug therapy (162) 162
neurosciences (162) 162
aged, 80 and over (158) 158
antiviral agents - administration & dosage (155) 155
administration, oral (153) 153
care and treatment (149) 149
amlodipine - therapeutic use (147) 147
therapy (147) 147
health aspects (146) 146
mortality (146) 146
blood-pressure (145) 145
valine - chemistry (145) 145
antihypertensive agents - pharmacology (143) 143
blood pressure (141) 141
follow-up studies (140) 140
angiotensin (138) 138
disease (135) 135
2-aminopurine - analogs & derivatives (132) 132
antihypertensive agents - adverse effects (132) 132
herpes zoster - drug therapy (131) 131
infectious diseases (131) 131
randomized controlled trials as topic (131) 131
valine - pharmacokinetics (130) 130
amino acids (129) 129
prevention (128) 128
rats, sprague-dawley (128) 128
angiotensin ii type 1 receptor blockers - pharmacology (127) 127
valine - metabolism (127) 127
young adult (125) 125
article (124) 124
2-aminopurine - therapeutic use (123) 123
herpes genitalis - drug therapy (122) 122
internal medicine (122) 122
methionine - genetics (122) 122
heart failure (120) 120
oncology (119) 119
hypertension - complications (114) 114
acyclovir - adverse effects (112) 112
psychiatry (112) 112
expression (110) 110
mutation (110) 110
genotype (109) 109
immunology (109) 109
amlodipine (108) 108
leucine (108) 108
child (107) 107
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2881) 2881
German (69) 69
French (51) 51
Chinese (35) 35
Russian (29) 29
Japanese (25) 25
Spanish (20) 20
Italian (6) 6
Hungarian (5) 5
Dutch (3) 3
Polish (3) 3
Swedish (3) 3
Finnish (2) 2
Danish (1) 1
Romanian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Heart Failure, ISSN 1388-9842, 08/2005, Volume 7, Issue 5, pp. 710 - 721
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of... 
Heart failure | Isosorbide dinitrate | Beta‐blockers | Digoxin | Angiotensin receptor blockers | Pharmacology | Aldosterone antagonists | Treatment | Eplerenone | Spironolactone | Hydralazine | ACE inhibitors | Clinical recommendations | Beta-blockers | VENTRICULAR SYSTOLIC DYSFUNCTION | heart failure | treatment | CARDIAC & CARDIOVASCULAR SYSTEMS | angiotensin receptor blockers | QUALITY-OF-CARE | hydralazine | eplerenone | isosorbide dinitrate | RANDOMIZED INTERVENTION TRIAL | beta-blockers | MEDICAL-TREATMENT | GENERAL-PRACTICE | digoxin | spironolactone | CONVERTING-ENZYME-INHIBITORS | clinical recommendations | CARDIAC-INSUFFICIENCY | pharmacology | NATIONAL-SURVEY | aldosterone antagonists | ELDERLY-PATIENTS | Benzopyrans - therapeutic use | Valsartan | Angiotensin Receptor Antagonists | Bisoprolol - therapeutic use | Humans | Carbazoles - administration & dosage | Heart Failure - physiopathology | Valine - administration & dosage | Enalapril - therapeutic use | Ethanolamines - administration & dosage | Indoles - administration & dosage | Ramipril - administration & dosage | Captopril - therapeutic use | Propanolamines - therapeutic use | Lisinopril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Ramipril - therapeutic use | Drug Therapy, Combination | Enalapril - administration & dosage | Spironolactone - therapeutic use | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Benzimidazoles - therapeutic use | Lisinopril - administration & dosage | Nebivolol | Valine - analogs & derivatives | Metoprolol - therapeutic use | Metoprolol - administration & dosage | Evidence-Based Medicine | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Bisoprolol - administration & dosage | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Stroke Volume | Benzopyrans - administration & dosage | Captopril - administration & dosage | Guideline Adherence | Ethanolamines - therapeutic use | Indoles - therapeutic use | Metoprolol - analogs & derivatives | Tetrazoles - therapeutic use | Valine - therapeutic use | Carbazoles - therapeutic use | Propanolamines - administration & dosage | Practice Guidelines as Topic | Prescription writing | Corticosteroids | Isosorbide mononitrate | Family medicine | Nitrates | Peptide hormones | Aldosterone | Preventive health services | Cardiac patients | Angiotensin | Antiandrogens | Medicine, Preventive | Steroids | Index Medicus | Kardiologi | converting-enzyme-inhibitors | Cardiac and Cardiovascular Systems | randomized intervention trial | quality-of-care | elderly-patients | cardiac-insufficiency | national-survey | medical-treatment | ventricular systolic dysfunction | general-practice
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 16, pp. 1477 - 1490
In this large clinical trial, the angiotensin-receptor blocker valsartan reduced the risk of diabetes in patients with impaired glucose tolerance. However, the... 
FASTING GLUCOSE | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | LIFE-STYLE INTERVENTIONS | DISEASE | PREVENTION | COMPONENTS | IMPAIRED GLUCOSE-TOLERANCE | MELLITUS | CONVERTING-ENZYME-INHIBITORS | Angiotensin II Type 1 Receptor Blockers - adverse effects | Follow-Up Studies | Phenylalanine - analogs & derivatives | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Body Weight - drug effects | Male | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Cyclohexanes - therapeutic use | Glucose Intolerance - drug therapy | Exercise | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Phenylalanine - therapeutic use | Drug Therapy, Combination | Hypoglycemic Agents - therapeutic use | Blood Glucose - analysis | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Diabetes Mellitus, Type 2 - prevention & control | Proportional Hazards Models | Blood Glucose - drug effects | Glucose Intolerance - diet therapy | Tetrazoles - therapeutic use | Valine - therapeutic use | Tetrazoles - adverse effects | Valine - adverse effects | Glucose Intolerance - therapy | Evaluation | Care and treatment | Glucose intolerance | Diabetes | Cardiovascular diseases | Drug therapy | Cardiovascular disease | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Lancet, The, ISSN 0140-6736, 10/2012, Volume 380, Issue 9851, pp. 1387 - 1395
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 16, pp. 1463 - 1476
Among patients with impaired glucose tolerance, the short-acting insulin secretagogue nateglinide did not reduce the incidence of diabetes over the course of 5... 
TRIAL | MEDICINE, GENERAL & INTERNAL | LIFE-STYLE | DIET | INSULIN-SECRETION | DISEASE | PREVENTION | IMPAIRED GLUCOSE-TOLERANCE | ACARBOSE | MELLITUS | NIDDM | Follow-Up Studies | Phenylalanine - adverse effects | Phenylalanine - analogs & derivatives | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Body Weight - drug effects | Male | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Cyclohexanes - therapeutic use | Glucose Intolerance - drug therapy | Exercise | Treatment Failure | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Cyclohexanes - adverse effects | Phenylalanine - therapeutic use | Drug Therapy, Combination | Hypoglycemic Agents - therapeutic use | Blood Glucose - analysis | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Diabetes Mellitus, Type 2 - prevention & control | Kaplan-Meier Estimate | Proportional Hazards Models | Blood Glucose - drug effects | Glucose Intolerance - diet therapy | Tetrazoles - therapeutic use | Valine - therapeutic use | Hypoglycemic Agents - adverse effects | Glucose Intolerance - therapy | Evaluation | Care and treatment | Glucose intolerance | Diabetes | Cardiovascular diseases | Drug therapy | Nateglinide | Studies | Cardiovascular disease | Index Medicus | Abridged Index Medicus | Clinical Medicine | Allmänmedicin | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | General Practice
Journal Article
The Lancet, ISSN 0140-6736, 06/2004, Volume 363, Issue 9426, pp. 2022 - 2031
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan... 
CALCIUM-CHANNEL BLOCKER | LIPID-LOWERING TREATMENT | RECEPTOR BLOCKER | MEDICINE, GENERAL & INTERNAL | ISOLATED SYSTOLIC HYPERTENSION | CONVERTING-ENZYME-INHIBITOR | DOUBLE-BLIND | ANGIOTENSIN-II | ELECTROCARDIOGRAPHIC IDENTIFICATION | CORONARY-ARTERY-DISEASE | BLOOD-PRESSURE | Calcium Channel Blockers - adverse effects | Valsartan | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Male | Sodium Chloride Symporter Inhibitors - therapeutic use | Angiotensin II Type 1 Receptor Blockers | Endpoint Determination | Diuretics | Female | Blood Pressure - drug effects | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Amlodipine - adverse effects | Treatment Outcome | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Amlodipine - therapeutic use | Antihypertensive Agents - adverse effects | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Tetrazoles - adverse effects | Valine - adverse effects | Hydrochlorothiazide - therapeutic use | Hypertension | Medical research | Side effects | Drug therapy | Drugs | Heart attacks | Heart surgery | Angioplasty | Risk | Cardiovascular disease | Blood | Randomization | Measurement techniques | Blood pressure | Heart diseases | Age | Heart failure | Edema | Stroke | Mortality | Medical treatment | Health risks | Angina pectoris | Patients | Coronary artery disease | Morbidity | Hypotheses | Coronary vessels | Diabetes | Cardiovascular diseases | Health risk assessment | Mercury | ACE inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2014, Volume 63, Issue 5, pp. 447 - 456
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 370, Issue 9583, pp. 221 - 229
Journal Article